In patients with renal insufficiency associated with increased hemoglobin levels and polycythemia, the possibilities of recombinant erythropoietin overdosing and disorders such as neoplasms and ...

A panelist discusses how caregivers can support patients with polycythemia vera (PV) by helping track symptoms, managing medical appointments and recognizing warning signs that require physician ...

A panelist discusses how polycythemia vera (PV) impacts daily life and lifestyle management, including beneficial changes ...

JMP Securities reiterated its Market Outperform rating on Protagonist Therapeutics (NASDAQ:PTGX) with a steady price target ...

Truist Securities reiterated its Buy rating and $60.00 price target for Protagonist Therapeutics (NASDAQ:PTGX) shares, which currently trade at $38.78 with a market capitalization of $2.3 billion. The ...

Itchy skin commonly occurs with polycythemia vera. Treatment may include medications, UV therapy, and lifestyle changes, such as applying moisturizer and avoiding triggers. One of the most common ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...

Hypoxia, a condition characterized by reduced oxygen availability, has been widely studied for its potential therapeutic ...

H.C. Wainwright analyst Patrick Trucchio reiterates a Buy rating and $75 price target on Silence Therapeutics (SLN) shares following a recent ...

Tokio Marine Asset Management Co. Ltd. increased its holdings in shares of Incyte Co. (NASDAQ:INCY – Free Report) by 7.1% ...

Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) had its price target lifted by analysts at JPMorgan Chase & Co. from $51.00 to $53.00 in a research note issued to investors on ...

Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the third quarter of fiscal year 2024 (nine months ended ...